Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study

Safety of Dynavax's hepatitis B vaccine gets thumbs up from US FDA advisory committee, but panel remained concern that postmarketing proposal doesn't address questions about potential link to cardiovascular events.